Vetter Serializes the First Product for South Korea
Vetter has announced the manufacture of the first commercial batches with single-use identification numbers. Following the introduction of a comprehensive serialization service last year, the company has now implemented product serialization for secondary packaging. In accordance with the requirements from the South Korean Ministry of Food and drug safety (MFDS) Vetter's solution identifies the drugs on the folding boxes via a 2-D data matrix code with a serial number, GTIN, expiry date, and batch number.
As the number of counterfeit drugs continues to grow, regulatory authorities around the world are increasingly relying on clear identification of products through serialization. They are demanding that the smallest packaging unit be marked with a single-use identification number. South Korea is among those countries requiring serialization with an aim towards protecting against counterfeiting, as well as a more secure supply chain.
"Together with our customer, we prepared for these requirements very early on," says Thomas Otto, managing director at Vetter. "We have been active in filling and final packaging for the company for years. Thanks to our serialization service, our partner can now meet the regulatory requirements for South Korea. We are, however, also aware of the fact that regulatory requirements differ from one country to the next. Therefore, we offer pharma and biotech companies a wide range of options that will give them flexibility when reacting to different regulatory standards."
Other news from the department manufacturing
Most read news
More news from our other portals
Last viewed contents
Discovery of molecular switch for protein production - Scientists show how bacteria control their protein biosynthesis through cell metabolism – possible approach for developing novel therapies
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
New structure to strengthen growth
Scientists open doors to diagnosis of emphysema - EMBL development may provide powerful new test for inflammatory lung diseases
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.
